Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 7/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22976805 | 1.00 | IDO1 (0.34) | IDO1IRAK4CHRNA1CYP2C8CYP2C9 | |
| SCHEMBL22976800 | 1.00 | IDO1 (0.34) | IDO1IRAK4CHRNA1CYP2C8CYP2C9 | |
| SCHEMBL22976565 | 0.93 | IRAK4 (0.34) | IDO1IRAK4JAK2NTRK1SMYD3 | |
| SCHEMBL22976559 | 0.93 | IRAK4 (0.34) | IDO1IRAK4JAK2NTRK1SMYD3 | |
| SCHEMBL22976562 | 0.93 | IRAK4 (0.34) | IDO1IRAK4JAK2NTRK1SMYD3 | |
| SCHEMBL29653581 | 0.90 | RAF1 (0.34) | IDO1IRAK4CHRNA1CYP2C8CYP2C9 | |
| SCHEMBL22976438 | 0.90 | KCNK3 (0.33) | IDO1IRAK4JAK2NTRK1SMYD3 | |
| SCHEMBL22976439 | 0.90 | KCNK3 (0.33) | IDO1IRAK4JAK2NTRK1SMYD3 | |
| SCHEMBL22976435 | 0.90 | KCNK3 (0.33) | IDO1IRAK4JAK2NTRK1SMYD3 | |
| SCHEMBL22976738 | 0.89 | IRAK4 (0.38) | IRAK4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013748-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2022-05-12 | — | — | US | disclosed |
| WO-2021030262-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | IDO1 2292/4885IRAK4 2170/4885CHRNA1 1101/4885 |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | IDO1 2292/4885IRAK4 2170/4885CHRNA1 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.